A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

HAEMATOLOGICA

FERRATA STORTI FOUNDATION

1. NCI-CTEP U01 Grant Program at MDACC
2. Celgene
3. Millennium/Takeda
4. National Stem Cell Foundation